PURPOSE: Disturbed peripheral blood B-cell homeostasis complicates certain infections and autoimmune diseases, such as HIV and systemic lupus erythematosus, but has not been reported in cancer. This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers. EXPERIMENTAL DESIGN: Flow cytometry was used to identify phenotypic differences in B cells from patients with melanoma and normal donors. In vitro stimulated B cells were assessed for responsiveness and also used as stimulators of allogeneic T cells in mixed lymphocyte reactions. RESULTS: We show B-cell dysregulation in patients with advanced melanoma (n = 26) and other solid tumors (n = 13), marked by a relative and absolute loss of CD27+ (memory) B cells and associated with an aberrant systemic plasmacytosis. Functionally, B cells from patients with melanoma inefficiently up-regulated immunoregulatory molecules and weakly secreted cytokines in response to CD40 and toll-like receptor 9 agonists. Stimulated B cells from patients induced proliferation of alloreactive CD4+ T cells, but these T cells poorly secreted IFNgamma and interleukin-2. These effects were recapitulated by using purified normal donor CD27(neg) B cells in these same assays, linking the predominance of CD27(neg) B cells in patients with the observed functional hyporesponsiveness. Indeed, B-cell dysfunction in patients strongly correlated with the extent of loss of CD27+ B cells in peripheral blood. CONCLUSIONS: Disturbed B-cell homeostasis is a previously unrecognized feature of patients with advanced melanoma and other cancers and may represent an unanticipated mechanism of immune incompetence in cancer.
PURPOSE: Disturbed peripheral blood B-cell homeostasis complicates certain infections and autoimmune diseases, such as HIV and systemic lupus erythematosus, but has not been reported in cancer. This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers. EXPERIMENTAL DESIGN: Flow cytometry was used to identify phenotypic differences in B cells from patients with melanoma and normal donors. In vitro stimulated B cells were assessed for responsiveness and also used as stimulators of allogeneic T cells in mixed lymphocyte reactions. RESULTS: We show B-cell dysregulation in patients with advanced melanoma (n = 26) and other solid tumors (n = 13), marked by a relative and absolute loss of CD27+ (memory) B cells and associated with an aberrant systemic plasmacytosis. Functionally, B cells from patients with melanoma inefficiently up-regulated immunoregulatory molecules and weakly secreted cytokines in response to CD40 and toll-like receptor 9 agonists. Stimulated B cells from patients induced proliferation of alloreactive CD4+ T cells, but these T cells poorly secreted IFNgamma and interleukin-2. These effects were recapitulated by using purified normal donorCD27(neg) B cells in these same assays, linking the predominance of CD27(neg) B cells in patients with the observed functional hyporesponsiveness. Indeed, B-cell dysfunction in patients strongly correlated with the extent of loss of CD27+ B cells in peripheral blood. CONCLUSIONS: Disturbed B-cell homeostasis is a previously unrecognized feature of patients with advanced melanoma and other cancers and may represent an unanticipated mechanism of immune incompetence in cancer.
Authors: D P Harris; L Haynes; P C Sayles; D K Duso; S M Eaton; N M Lepak; L L Johnson; S L Swain; F E Lund Journal: Nat Immunol Date: 2000-12 Impact factor: 25.606
Authors: Jianhua Ni; Edgardo Hembrador; Adrian M Di Bisceglie; Ira M Jacobson; Andrew H Talal; David Butera; Charles M Rice; Thomas J Chambers; Lynn B Dustin Journal: J Immunol Date: 2003-03-15 Impact factor: 5.422
Authors: M Odendahl; A Jacobi; A Hansen; E Feist; F Hiepe; G R Burmester; P E Lipsky; A Radbruch; T Dörner Journal: J Immunol Date: 2000-11-15 Impact factor: 5.422
Authors: Angela Malaspina; Susan Moir; Shyamasundaran Kottilil; Claire W Hallahan; Linda A Ehler; Shuying Liu; Marie A Planta; Tae-Wook Chun; Anthony S Fauci Journal: J Immunol Date: 2003-06-15 Impact factor: 5.422
Authors: Michael S von Bergwelt-Baildon; Robert H Vonderheide; Britta Maecker; Naoto Hirano; Karen S Anderson; Marcus O Butler; Zhinan Xia; Wan Y Zeng; Kai W Wucherpfennig; Lee M Nadler; Joachim L Schultze Journal: Blood Date: 2002-05-01 Impact factor: 22.113
Authors: Karin Tarte; John De Vos; Thomas Thykjaer; Fenghuang Zhan; Geneviève Fiol; Valérie Costes; Thierry Rème; Eric Legouffe; Jean-François Rossi; John Shaughnessy; Torben F Ørntoft; Bernard Klein Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Réjean Lapointe; Angélique Bellemare-Pelletier; Franck Housseau; Jacques Thibodeau; Patrick Hwu Journal: Cancer Res Date: 2003-06-01 Impact factor: 12.701
Authors: J Andrew Duty; Peter Szodoray; Nai-Ying Zheng; Kristi A Koelsch; Qingzhao Zhang; Mike Swiatkowski; Melissa Mathias; Lori Garman; Christina Helms; Britt Nakken; Kenneth Smith; A Darise Farris; Patrick C Wilson Journal: J Exp Med Date: 2008-12-22 Impact factor: 14.307
Authors: Hiroyoshi Doi; Tara K Iyer; Erica Carpenter; Hong Li; Kyong-Mi Chang; Robert H Vonderheide; David E Kaplan Journal: Hepatology Date: 2012-01-19 Impact factor: 17.425
Authors: Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff Journal: Cancer Res Date: 2012-01-19 Impact factor: 12.701
Authors: Hans A Schlößer; Martin Thelen; Axel Lechner; Kerstin Wennhold; Maria A Garcia-Marquez; Sacha I Rothschild; Elena Staib; Thomas Zander; Dirk Beutner; Birgit Gathof; Ramona Gilles; Engin Cukuroglu; Jonathan Göke; Alexander Shimabukuro-Vornhagen; Uta Drebber; Alexander Quaas; Christiane J Bruns; Arnulf H Hölscher; Michael S Von Bergwelt-Baildon Journal: Oncoimmunology Date: 2018-11-02 Impact factor: 8.110
Authors: Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane Journal: J Immunol Date: 2018-05-11 Impact factor: 5.422
Authors: Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz Journal: Prostate Date: 2010-03-01 Impact factor: 4.104
Authors: Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher Journal: Oncotarget Date: 2014-04-15
Authors: Niki Karachaliou; Sara Pilotto; Cristina Teixidó; Santiago Viteri; María González-Cao; Aldo Riso; Daniela Morales-Espinosa; Miguel Angel Molina; Imane Chaib; Mariacarmela Santarpia; Eduardo Richardet; Emilio Bria; Rafael Rosell Journal: Ann Transl Med Date: 2015-10